Venlafaxine versus other anti-depressive agents for depression.
Andrea Cipriani, Alessandra Signoretti, Toshi A Furukawa, Rachel Churchill, Silva Tomelleri, Ichiro M Omori, Hugh McGuire, Corrado Barbui
Author Information
Andrea Cipriani: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.
Alessandra Signoretti: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.
Toshi A Furukawa: Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Rachel Churchill: Academic Unit of Psychiatry, Community Based Medicine, University of Bristol, Bristol, UK.
Silva Tomelleri: Department of Medicine and Public Health, Section of Psychiatry, University of Verona, Verona, Italy.
Ichiro M Omori: Cochrane Schizophrenia Group, University of Nottingham, Nottingham, UK.
Hugh McGuire: National Coordinating Centre for Women and Child Health, London, UK.
Corrado Barbui: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the efficacy of venlafaxine depressive agents in alleviating the acute symptoms of major depressive disorder .To review acceptability of treatment with venlafaxine depressive agents .To investigate the adverse effects of venlafaxine depressive agents .
Ann Pharmacother. 2004 Apr;38(4):579-85
[PMID: 14982982 ]
Arch Gen Psychiatry. 1962 Dec;7:407-17
[PMID: 13931376 ]
Cochrane Database Syst Rev. 2000;(4):CD002791
[PMID: 11034764 ]
JAMA. 2003 Aug 20;290(7):921-8
[PMID: 12928469 ]
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
[PMID: 14399272 ]
BMJ. 2003 May 31;326(7400):1167-70
[PMID: 12775614 ]
Int Clin Psychopharmacol. 1997 Mar;12(2):99-108
[PMID: 9219045 ]
Ann Intern Med. 2005 Sep 20;143(6):415-26
[PMID: 16172440 ]
Cochrane Database Syst Rev. 2003;(2):CD004186
[PMID: 12804503 ]
Br J Psychiatry. 2002 May;180:396-404
[PMID: 11983635 ]
Can J Psychiatry. 2004 Sep;49(9):601-6
[PMID: 15503731 ]
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114
[PMID: 20238342 ]
CMAJ. 2004 Feb 17;170(4):477-80
[PMID: 14970094 ]
J Clin Psychiatry. 2006 Jun;67(6):850-64
[PMID: 16848644 ]
Eur J Clin Pharmacol. 2004 Nov;60(9):629-34
[PMID: 15448956 ]
Int J Epidemiol. 2002 Feb;31(1):72-6
[PMID: 11914297 ]
Neuropsychopharmacology. 2003 Mar;28(3):552-7
[PMID: 12629536 ]
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004185
[PMID: 16235353 ]
J Clin Psychopharmacol. 2004 Apr;24(2):126-30
[PMID: 15206658 ]
Br J Psychiatry. 1979 Apr;134:382-9
[PMID: 444788 ]
J Clin Epidemiol. 2006 Jan;59(1):7-10
[PMID: 16360555 ]
Ann Intern Med. 1992 Jan 1;116(1):78-84
[PMID: 1530753 ]
J Psychopharmacol. 2000 Mar;14(1):3-20
[PMID: 10757248 ]
J Psychiatr Res. 2004 Nov-Dec;38(6):577-82
[PMID: 15458853 ]
Soc Sci Med. 1998 Jun;46(12):1569-85
[PMID: 9672396 ]
Br J Psychiatry. 1999 Apr;174:297-303
[PMID: 10533547 ]
Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45
[PMID: 10767867 ]
BMJ. 1996 Nov 9;313(7066):1200
[PMID: 8916759 ]
Ann Intern Med. 2000 May 2;132(9):743-56
[PMID: 10787370 ]
Aust N Z J Psychiatry. 2004 Jun;38(6):389-407
[PMID: 15209830 ]
Cochrane Database Syst Rev. 2000;(2):CD001851
[PMID: 10796826 ]
Int Clin Psychopharmacol. 2005 Jan;20(1):49-52
[PMID: 15602117 ]
Control Clin Trials. 2004 Dec;25(6):598-612
[PMID: 15588746 ]
J Clin Psychiatry. 2005 Jun;66(6):750-5
[PMID: 15960569 ]
Am J Psychiatry. 2005 Oct;162(10):1957-60
[PMID: 16199844 ]
BMJ. 2002 Nov 2;325(7371):991
[PMID: 12411354 ]
BMJ. 2003 Sep 6;327(7414):557-60
[PMID: 12958120 ]
